{
    "nctId": "NCT00174343",
    "briefTitle": "Exemestane As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients",
    "officialTitle": "Phase II Study Evaluating The Role Of Exemestane On Clinical And Pathologic Response Rates, And Its Aromatase Activity As Treatment In Neoadjuvant Setting For Operable Breast Cancer Patients.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 46,
    "primaryOutcomeMeasure": "To evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (Aromasin\u00ae)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Post-menopausal patients with unilateral breast cancer T2 to T4, N0-1, M0, non inflammatory, operable, hormonal receptors positive\n\nExclusion Criteria:\n\n* Patients with bilateral breast cancer T4d, inflammatory, non operable, hormonal receptors negative",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}